Affiliations 

  • 1 Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 2 Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, Spain
  • 3 Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 4 Department of Chemistry, Gebze Technical University, P.O Box 141, Gebze, Kocaeli, Turkey
  • 5 Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 6 Department of Chemistry, Gebze Technical University, P.O Box 141, Gebze, Kocaeli, Turkey. Electronic address: [email protected]
  • 7 Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe (CIPF), Av. Eduardo Primo Yúfera 3, Valencia, Spain. Electronic address: [email protected]
  • 8 Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Electronic address: [email protected]
Nanomedicine, 2017 05;13(4):1447-1458.
PMID: 28214608 DOI: 10.1016/j.nano.2017.02.002

Abstract

In photodynamic therapy (PDT), the low absorptivity of photosensitizers in an aqueous environment reduces singlet oxygen generation efficiency and thereby decreases photosensitizing efficacy in biological conditions. To circumvent this problem, we designed a phthalocyanine-poly-L-glutamic acid conjugate (1-PG) made from a new phthalocyanine (Pc 1) monofunctionalized to allow adequate conjugation to PGA. The resulting 1-PG conjugate retained high absorptivity in the near-infrared (NIR) region at its λmax675nm in an aqueous environment. The 1-PG conjugate demonstrated good singlet oxygen generation efficiency, increased uptake by 4 T1 breast cancer cells via clathrin-mediated endocytosis, and enhanced photocytotoxic efficacy. The conjugate also displayed a high light-dark toxicity ratio, approximately 1.5-fold greater than zinc phthalocyanine at higher concentration (10 μM), an important feature for the reduction of dark toxicity and unwanted side effects. These results suggest that the 1-PG conjugate could be a useful alternative for deep tissue treatment with enhanced anti-cancer (PDT) efficacy.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.